secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK:        0000875320
Form:       8-K
Filed at:   2021-11-02T23:59:59+00:00
Accession:  0000875320-21-000031
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vertex Q3 revenue $1.98B (+29% YoY); raises FY2021 guidance to $7.4-7.5B
------------------------------------------------------------------------

- Product revenues of $1.984B (+29% YoY); GAAP diluted EPS $3.28, Non-GAAP $3.56.
- Raised FY2021 product revenue guidance to $7.4-7.5B from prior $7.2-7.4B.
- TRIKAFTA/KAFTRIO net revenues $1.556B, up 62% YoY from $960M.
- Pipeline: VX-880 T1D positive data (1st patient); VX-147 Phase 2 results Q4; VX-548 data Q1 2022.
- CTX001 target enrollment achieved in TDT and SCD trials; regulatory submissions planned late 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875320/000087532021000031/0000875320-21-000031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875320/000087532021000031/vrtx-20211102.htm
  HTML page:      https://secwatch.observer/filing/0000875320-21-000031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer